Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord-derived Mesenchymal Stem Cells for Ischemic Stroke
NCT04811651Phase 2Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Mar 2021
- Primary completion
- Jul 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human umbilical cord mesenchymal stem cells in ischemic stroke (2 arms), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Proportion of modified Rankin Scale (mRS) 0-2 at 90 days. Started Mar 2021; status: completed.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04811651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811651.